Wellington Management, an investment management firm, led a $100m Series C funding round in Gracell Biotechnology, a biopharmaceutical company. The round was also joined by OrbiMed, Morningside Ventures, Vivo Capital, Temasek Holdings, Lilly Asia Ventures and King Star Med. "We are very pleased to expand our investor base with support from a high caliber consortium. Our passion is to bring transformative CAR-T cell therapies to a broader group of patients by developing products that are efficacious and can be made widely available," William Wei Cao, Gracell Founder, Chairman and CEO.